Robert C O'Donnell

US Patent:

20010019828, Sep 6, 2001

Filed:

Apr 10, 2001

Appl. No.:

09/832510

Inventors:

Larry Rose - Carmichael CA, US
Claude Meares - Davis CA, US
Robert O'Donnell - Sacramento CA, US

International Classification:

C12Q001/68
G01N033/574
A61K039/00

US Classification:

435/006000, 435/007230, 424/184100

Abstract:

This invention provides novel peptide epitopes recognized by the non-Hodgkin's B cell lymphoma reactive Lym-1 antibody. These novel peptide epitopes are capable of generating antibodies directed against Lym-1 peptide epitope expressing B-NHL cells. This invention is also directed to the treatment of B-NHL.

US Patent:

20120121612, May 17, 2012

Filed:

May 20, 2010

Appl. No.:

13/320898

Inventors:

Joseph Tuscano - Folsom CA, US
Derick Lau - Roseville CA, US
Robert O'Donnell - Sacramento CA, US
Yunpeng Ma - Sichuan, CN

Assignee:

UNITED STATES GOVERNMENT AS THE REPRESENTED BY THE - WASHINGTON DC
REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA

International Classification:

A61K 38/02
A61K 38/48
A61K 39/395
A61K 38/52
A61P 35/00
C12N 5/09
A61K 38/44

US Classification:

4241741, 514 193, 435375, 514 194, 424 9463, 424 944, 424 945

Abstract:

The present invention provides compositions comprising the component of fermented wheat germ extract (“FWGE”) active in reducing, inhibiting or preventing the proliferation of cancer cells and/or tumors, and methods of making and using such compositions. The active component from FWGE comprises polypeptides having a molecular weight in the range of about 5-100 kiloDaltons (kD), for example, a molecular weight in the range of about 12-50 kD. Exemplary polypeptides from FWGE determined to be active in reducing, inhibiting or preventing the proliferation of cancer cells and/or tumors are listed in Table 1.

US Patent:

62178717, Apr 17, 2001

Filed:

Oct 28, 1998

Appl. No.:

9/181896

Inventors:

Larry M. Rose - Carmichael CA
Claude F. Meares - Davis CA
Robert T. O'Donnell - Sacramento CA

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 3900

US Classification:

4241841

Abstract:

This invention provides novel peptide epitopes recognized by the non-Hodgkin's B cell lymphoma reactive Lym-1 antibody. These novel peptide epitopes are capable of generating antibodies directed against Lym-1 peptide epitope expressing B-NHL cells. This invention is also directed to the treatment of B-NHL.

US Patent:

20200165353, May 28, 2020

Filed:

Aug 8, 2019

Appl. No.:

16/535855

Inventors:

- Oakland CA, US
Robert O'DONNELL - Sacramento CA, US

International Classification:

C07K 16/30
C07K 16/28

Abstract:

This invention provides methods for preventing, reducing, delaying or inhibiting the proliferation and/or growth and/or metastasis of lung cancers and prostate cancer that express or overexpress CD22 by contacting the lung cancer cell or prostate cancer cell with an antigen binding molecule that binds to CD22 expressed on the surface of the cancer cell.

US Patent:

20140248278, Sep 4, 2014

Filed:

Jun 8, 2012

Appl. No.:

14/123756

Inventors:

Joseph Tuscano - Folsom CA, US
Robert O'Donnell - Sacramento CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

C07K 16/30

US Classification:

4241441, 435375, 435366

Abstract:

This invention provides methods for preventing, reducing, delaying or inhibiting the proliferation and/or growth and/or metastasis of lung cancers and prostate cancer that express or overexpress CD22 by contacting the lung cancer cell or prostate cancer cell with an antigen binding molecule that binds to CD22 expressed on the surface of the cancer cell.